Search results for Ibalizumab ELISA Kit
Ibalizumab ELISA Kit, ProteoGenix, KPTX136
Description of Ibalizumab ELISA Kit The Structure of Ibalizumab ELISA Kit Ibalizumab ELISA Kit is a highly sensitive and specific enzyme-linked immunosorbent assay (ELISA) kit designed for the detection and quantification of Ibalizumab, a monoclonal antibody used as a therapeutic agent in the treatment of HIV-1 infection. The kit is composed of several components including a microplate coated with Ibalizumab-specific antibodies, a detection antibody, and a colorimetric substrate for signal detection. The microplate used in the Ibalizumab ELISA Kit is made of polystyrene and has 96 wells, each of which is coated with a specific amount of Ibalizumab-specific antibodies. These antibodies are produced through recombinant DNA technology and are highly specific for Ibalizumab, ensuring accurate and reliable results. The microplate is designed to capture and bind Ibalizumab present in the sample, allowing for the quantification of the antibody. The detection antibody used in the kit is a biotinylated monoclonal antibody that specifically binds to Ibalizumab. This antibody is labeled with biotin, a vitamin B derivative, which allows for its detection through the use of a streptavidin-horseradish peroxidase (HRP) conjugate. The HRP enzyme catalyzes a colorimetric reaction with the substrate, producing a visible signal that can be measured and quantified. The Activity of Ibalizumab ELISA Kit The Ibalizumab ELISA Kit is a highly sensitive and specific tool for the detection and quantification of Ibalizumab in various biological samples, including serum, plasma, and cell culture supernatants. The kit has a wide dynamic range of detection, allowing for the accurate measurement of Ibalizumab levels in both high and low concentrations. The activity of the Ibalizumab ELISA Kit is based on the principle of competitive ELISA, where the amount of Ibalizumab present in the sample competes with a fixed amount of Ibalizumab conjugated to the microplate for binding to the detection antibody. The signal produced is inversely proportional to the amount of Ibalizumab present in the sample, allowing for the quantification of the antibody. The sensitivity of the kit is enhanced by the use of a highly specific detection antibody and a colorimetric substrate that produces a strong signal. This allows for the detection of Ibalizumab in samples with low concentrations, making the kit suitable for both research and clinical applications. The Application of Ibalizumab ELISA Kit The Ibalizumab ELISA Kit has several applications, including the measurement of Ibalizumab levels in patient samples for monitoring treatment response and the evaluation of pharmacokinetics and pharmacodynamics of Ibalizumab in clinical trials. The kit can also be used in research studies to assess the presence and levels of Ibalizumab in different biological samples. One of the major applications of the Ibalizumab ELISA Kit is in the development and evaluation of Ibalizumab as a therapeutic agent for the treatment of HIV-1 infection. Ibalizumab is a monoclonal antibody that targets the CD4 binding site of the HIV-1 virus, preventing it from entering and infecting host cells. The ELISA kit allows for the measurement of Ibalizumab levels in patient samples, providing valuable information on its efficacy and pharmacokinetics. In addition, the Ibalizumab ELISA Kit can also be used to assess the potential for drug-drug interactions between Ibalizumab and other medications in co-treated patients. This is important for the safe and effective use of Ibalizumab in combination therapy with other antiretroviral drugs. In conclusion, the Ibalizumab ELISA Kit is a valuable tool for the detection and quantification of Ibalizumab, providing important information for both research and clinical applications
Host
Reactivity
Applications
Conjugation
Ibalizumab ELISA Kit, Abbexa, abx395025
Ibalizumab ELISA Kit is a quantitative ELISA kit for detection of Ibalizumab.Ibalizumab, a recombinant humanized monoclonal antibody, represents the first novel agent for HIV-1 management in over a decade and is the first monoclonal antibody for the treatment of MDR HIV-1 infection in combination with other forms of antiretroviral therapy in heavily treatment-experienced adults who are failing their current antiretroviral regimen. Ibalizumab demonstrates a novel mechanism of action as a CD4-directed postattachment inhibitor and has a favorable pharmacokinetic profile that allows for a dosing interval of every 14 days after an initial loading dose. Clinical studies have demonstrated reasonably substantial antiretroviral activity with ibalizumab among a complex patient population with advanced HIV-1 infection who are receiving an optimized background regimen, where limited therapeutic options exist. Ibalizumab was well tolerated in clinical trials, and the most common adverse effects included diarrhea, nausea, dizziness, fatigue, pyrexia, and rash. Resistance to ibalizumab has also been observed via reduced expression or loss of the potential N-linked glycosylation sites in the V5 loop of the envelope glycoprotein 120. The mechanism of action, pharmacokinetic parameters, efficacy, and safety of ibalizumab present an advance in the management of MDR HIV-1 infection. Future studies and postmarketing experience will further determine longer-term clinical efficacy, safety, and resistance data for ibalizumab.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Please provide the required information below so that we can quickly source your products.